Breast Cancer | Specialty

Enobosarm May Represent a Safe, New Hormone Treatment Approach for AR+, ER+ Metastatic Breast Cancer

July 6th 2021

Hannah M. Linden, MD, discusses the potential for enobosarm in patients with metastatic breast cancer, data from a phase 2 trial examining its use, and next steps for the agent in the paradigm.

FDA Supports Continued Development of Oral Paclitaxel/Encequidar in Metastatic Breast Cancer

July 6th 2021

Athenex, Inc. held a Type A meeting with the FDA to discuss the deficiencies raised in the complete response letter issued in March 2021 for the new drug application for oral paclitaxel plus encequidar in the treatment of patients with metastatic breast cancer.

The HER2CLIMB Study in HER2+ MBC

July 6th 2021

The significance of the HER2CLIMB study of tucatinib in combination with capecitabine and trastuzumab as treatment for patients with HER2-positive metastatic breast cancer.

Current Standard of Care for HER2+ MBC

July 6th 2021

Current treatment approaches available to treat HER2-positive metastatic breast cancer in the first- and second-line treatment settings.

Yale Cancer Center Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers

July 6th 2021

The Future of Breast Cancer Surgery Is Here

July 5th 2021

Thanks to advances in research, targeted therapies, and a more personalized approach to treating patients diagnosed with breast cancer, more surgical options exist for patients with breast cancer patients than ever before.

Dr. Williams on the Role of PI3K Inhibitors in HR+/HER2- Breast Cancer

July 1st 2021

Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Adjuvant Advances Shine at ASCO 2021

July 1st 2021

Novel therapeutic strategies are poised to expand in adjuvant settings for patients with early-stage disease facing recurrence risks in the treatment paradigms for a range of tumor types after positive data from large phase 3 clinical trials were highlighted at the 2021 American Society of Clinical Oncology Annual Meeting

Management of HR+ mBC: Key Prognostic Factors

June 30th 2021

Considerations for approaching the treatment of HR-positive metastatic breast cancer through insights on key prognostic factors.

Role of Molecular Profiling in HR+ Metastatic Breast Cancer

June 30th 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss when it is appropriate to order molecular testing and the impact of testing on the treatment of HR-positive metastatic breast cancer.

Balixafortide Plus Eribulin Fails to Improve ORR in Advanced HER2-Negative Breast Cancer

June 28th 2021

The combination of balixafortide and eribulin did not significantly improve objective response rate over eribulin alone in the treatment of patients with HER2-negative, locally recurrent or metastatic breast cancer, missing the co-primary end point of the phase 3 FORTRESS study.

Internationally Renowned Breast Cancer and HIV-Associated Malignancy Expert to Join Mount Sinai

June 28th 2021

Joseph Sparano, MD, will lead Hematology and Medical Oncology and will be Deputy Director of The Tisch Cancer Institute.

Dr. Pederson on the Importance of Ancestrally-Unbiased Polygenic Risk Assessment in Breast Cancer

June 24th 2021

Holly Pederson, MD, discusses the importance of ancestrally-unbiased polygenic risk assessment in patients with breast cancer.

Dr. Bardia on the Rationale for the AMEERA-5 Trial in ER+/HER2- Breast Cancer

June 24th 2021

Aditya Bardia, MD, MPH, discusses the rationale for the ongoing phase 3 AMEERA-5 trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Schram on the Results of the Phase 1/2 eNRGy Trial in NRG1+ Solid Tumors

June 24th 2021

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Dr. Simons on Racial Disparities Reported in Luminal Breast Cancer

June 22nd 2021

Yael Simons, MD, discusses the racial disparities seen in African Americans patients with luminal breast cancer.

Dr. Garber on the Efficacy of Adjuvant Olaparib in High-Risk, HER2-Negative Breast Cancer

June 22nd 2021

Judy Garber, MD, MPH, discusses the efficacy of adjuvant olaparib in patients with high-risk, HER2-negative breast cancer, as demonstrated in the phase 3 OlympiA trial.

Matsen Reflects on Changes to Breast Cancer Surgery During COVID-19

June 21st 2021

Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.

Rapid Readouts: Final Results From the Phase 3 PROTECTIVE-2 Trial

June 18th 2021

Douglas W. Blayney, MD, presents data from the 2021 American Society of Clinical Oncology Annual Meeting on the final results from the phase 3 PROTECTIVE-2 trial of Plinabulin and Pegfilgrastim in breast cancer patients treated with high febrile neutropenia risk chemotherapy.

Dr. Blanter on Racial Disparities in Development of Distant Metastases in Breast Cancer

June 18th 2021

Julia Blanter, MD, discusses the risk of developing distant metastases after initial breast cancer diagnosis among Black vs White women.